Skip to main content
S 2944 108th Congress Senate

A bill to provide that no funds may be expended by the United States Trade Representative to negotiate data exclusivity provisions for certain pharmaceutical products.

Introduced: October 8, 2004 Introduced by: Wyden, Ron Democratic · Oregon See on congress.gov
Foreign Trade and International Finance AIDS (Disease)Clinical trialsCommerceDrug approvals
More subjectsShow fewer subjects
Drug industryDrugsEmergency ManagementEmergency medicineEpidemicsGeneric drugsGovernment Operations and PoliticsHealthHuman immunodeficiency virusesInternational AffairsMalariaOffice of the U.S. Trade RepresentativeTrade agreementsTrade negotiationsTuberculosis
Sign in to write a letter Sign in to watch
This bill died when the 108th Congress ended
It never became law before the 108th Congress (2003–2004) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 8, 2004
Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S10848)
Oct 8, 2004
Sponsor introductory remarks on measure. (CR S10847-10848)
Oct 8, 2004
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 8, 2004

Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S10848)

 Plain-English summary Congressional Research Service

Prohibits funds appropriated or otherwise obligated to the U.S. Trade Representative from being expended to negotiate data exclusivity provisions with any country with respect to public health pharmaceutical products or to require actions of another country which interfere with a country's access to such products.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2944: A bill to provide that no funds may be expended by the United States Trade Representative to negotiate data exclusivity provisions for certain pharmaceutical products.. 108th Congress. Open America. https://openamerica.io/bill/108-S-2944/
MLA
"S. 2944: A bill to provide that no funds may be expended by the United States Trade Representative to negotiate data exclusivity provisions for certain pharmaceutical products.." 108th Congress, 2026, Open America, https://openamerica.io/bill/108-S-2944/.
Bluebook (legal)
S. 2944, 108th Cong. (2026), https://openamerica.io/bill/108-S-2944/.
Markdown link
[S. 2944: A bill to provide that no funds may be expended by the United States Trade Representative to negotiate data exclusivity provisions for certain pharmaceutical products.](https://openamerica.io/bill/108-S-2944/)
Report a problem